Status:
TERMINATED
Efficacy and Mechanism of Action of Methenamine Hippurate (Hiprex™) in Women With Recurring Urinary Tract Infections.
Lead Sponsor:
University of Texas Southwestern Medical Center
Conditions:
Urinary Tract Infections
Eligibility:
FEMALE
50-85 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to measure the concentration of formaldehyde in the urine of women with recurrent urinary tract infections on Hiprex; and then, assuming its urinary presence is confirmed ...
Eligibility Criteria
Inclusion
- Female
- Age 50 - 85
- Have RUTIs (at least 2 UTIs within the past 6 months or 3 within the past year) -
Exclusion
- Being on antibiotics at baseline (i.e. suppressive therapy or antibiotic therapy for urinary or non-urinary infections)
- Neurogenic bladder condition
- Using urinary catheters (including Foley catheter, intermittent catheterization, and suprapubic catheter)
- Uncontrolled diabetes (HbA1c \> 9)
- Chronic renal failure defined as serum creatinine \> 1.5 mg/dL
- History of liver disease
- Patients from out of town, in whom follow-up will not be possible
- Pregnancy
- Allergy to Hiprex
- Inability to take Hiprex reliably at home, such as having psychosis, dementia, or swallowing disorders
- Non-English speakers -
Key Trial Info
Start Date :
January 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT04709601
Start Date
January 4 2021
End Date
December 31 2024
Last Update
January 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT-Southwestern Medical Center
Dallas, Texas, United States, 75390